Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today
Alnylam Pharmaceuticals (ALNY) stock rose 6.9% after the company shared positive long-term data for AMVUTTRA, reinforcing its cardiovascular benefits. The company also reiterated 2026 guidance and authorized a $1 billion share repurchase program, signaling confidence. Insider and institutional trading activity was noted, with mixed positions.
How this was made

The 30-second read
Why it matters
The data addresses a key efficacy endpoint, likely improving market perception and supporting the stock's recent rally.
Market read
The announcement provides fresh, material information that directly moves ALNY's price, making it a high‑impact trading signal.
What to watch
Potential regulatory review timeline and reimbursement uncertainty could temper upside.
Background
Alnylam announced new long‑term data from its HELIOS‑B trial for AMVUTTRA in ATTR‑CM and a $1 bn share repurchase program.
Ticker impact
ALNY jumped 6.9% as new five‑year HELIOS‑B data showed mortality benefit for AMVUTTRA and the board announced a $1 bn share repurchase.
upward bias as investors price in durable cardiovascular benefit and undervaluation perception.
Clinical data is a material catalyst for a biotech; combined with a sizable repurchase program it supports further upside.
Market effects
Strengthens outlook for the rare‑disease and cardiovascular biotech subsectors.
Positive for US biotech equities, modest spillover to related pharma stocks.
Limited to investors focused on biotech and specialty pharma.
Counterpoint
Skeptics may question durability of mortality benefit and potential pricing pressure from upcoming competition.
Key entities
- companyAlnylam Pharmaceuticals
US‑listed biotech developing RNAi therapies.

